Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema vs Ozempic in Type 2 Diabetes (China cohort of global phase 3)
CTR20220767Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of icosema in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 52. Started Apr 2022; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20220767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220767.